An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine
- PMID: 6427704
An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine
Abstract
The antibody response of a group of adult volunteers given a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine, has been studied by the ELISA technique. The antigen was an outer membrane preparation from a non-capsular strain of Neisseria meningitidis (the vaccine strain). The vaccination was performed as a double-blind experiment where one group of 27 persons was given the vaccine and a similar group of 28 persons was given a placebo. In addition, five volunteers from the laboratory staff were given the vaccine. Two weeks after the primary vaccination, 31 of the 32 vaccinated persons demonstrated a significant increase of specific IgG antibodies. The number with significant IgA and IgM increase was 21 and 12, respectively. A booster effect after revaccination four weeks later was found in 18 persons for IgG, in 10 for IgA and in one for IgM. Twenty-five weeks after the primary vaccination the ELISA values were significantly reduced, mostly for IgM antibodies. The mean values for IgG, IgM and IgA were then 150%, 130% and 110%, respectively, of the values before vaccination. A new way of analysing the data has also been tried for IgG determination. Instead of comparing OD values, we calculate the expression: B = D/2 . In(1 + OD/A)/(1-OD/A), where A is an experimental constant and D is the serum dilution. B then becomes linearly proportional to the antibody concentration. This way of expressing the results shows the geometric mean IgG titer 25 weeks after vaccination to be three times higher for the vaccinated than for the placebo group.
Similar articles
-
Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982.NIPH Ann. 1983 Dec;6(2):133-8. NIPH Ann. 1983. PMID: 6427703 Clinical Trial.
-
Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.J Clin Invest. 1979 May;63(5):836-48. doi: 10.1172/JCI109383. J Clin Invest. 1979. PMID: 109466 Free PMC article.
-
Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.NIPH Ann. 1991 Dec;14(2):169-79; discussion 180-1. NIPH Ann. 1991. PMID: 1687481
-
Control of meningococcal meningitis with meningococcal vaccines.Yale J Biol Med. 1975 Jul;48(3):197-200. Yale J Biol Med. 1975. PMID: 808913 Free PMC article. Review.
-
The immune response to the capsular polysaccharide of Neisseria meningitidis group B.Zentralbl Bakteriol. 1997 Feb;285(3):331-40. doi: 10.1016/s0934-8840(97)80001-1. Zentralbl Bakteriol. 1997. PMID: 9084108 Review. No abstract available.
Cited by
-
Human immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccine.J Clin Microbiol. 1987 Aug;25(8):1349-53. doi: 10.1128/jcm.25.8.1349-1353.1987. J Clin Microbiol. 1987. PMID: 3114315 Free PMC article.
-
Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.J Clin Microbiol. 1988 Aug;26(8):1543-8. doi: 10.1128/jcm.26.8.1543-1548.1988. J Clin Microbiol. 1988. PMID: 3139705 Free PMC article. Clinical Trial.
-
The meningococcus tamed?Arch Dis Child. 2002 Jul;87(1):13-7. doi: 10.1136/adc.87.1.13. Arch Dis Child. 2002. PMID: 12089113 Free PMC article.
-
Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting.Infect Immun. 1986 Feb;51(2):571-8. doi: 10.1128/iai.51.2.571-578.1986. Infect Immun. 1986. PMID: 3002987 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous